Список проголосовавших за комментарий " <ul><li><strong>AGRX</strong> -62.4% (announces 'positive' top-line results from its Phase 3 SECURE clinical trial of Twirla; plans to resubmit its NDA for Twirla in the first half of 2017 on the basis of the SECURE results)</li><li><strong>ACUR</strong> -10.7% (announces they are exploring a full range of financing and strategic alternatives, including a possible sale of the company)</li><li><strong>ARR</strong> -3% (announces January 2017 dividend rate per common share of $0.19 vs $0.22/share prior month)</li><li><strong>CLVS</strong> -2.7% (prices / upsizes public offering of 5 mln shares of common stock at $41/ per share)</li><li><strong>TSLA</strong> -1% (Misses Q4 delivery targets on production delays related to new autopilot hardware; net orders set new record)</li><li><strong>SFR</strong> +-0.5% (commences a private offering of $250 million aggregate principal amount of convertible senior notes due 2022)</li></ul>"